In the current study, we tested the hypothesis that the pan-class I PI3K/mTOR antagonist bimiralisib would result in cancer cell apoptosis and concomitant tumor shrinkage in NOTCH1-mutant HNSCC. Here, MTOR is linked to head and neck squamous cell carcinoma.